36
Participants
Start Date
May 15, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
Tislelizumab combined with two predefined dose groups of palbociclib
Tislelizumab, 200mg q3W, combined with two predefined dose groups of palbociclib: 100mg QD and 125mg QD, separately.
RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial.
After the exploration of Tislelizumab, 200mg q3W combined with palbociclib, and the maximal tolerated dose (MTD) was determined, then RP2D dose of Tislelizumab combined with palbociclib was selected for phase II clinical trial.
RECRUITING
Nanfang Hospital, Southern Medical University, Guangzhou
RECRUITING
Sun Yat-sen Memorial Hospital, Guangzhou
RECRUITING
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou
RECRUITING
The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou
RECRUITING
Zhujiang Hospital of Southern Medical University, Guangzhou
RECRUITING
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
Xiangya Hospital, Central South University, Changsha
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
OTHER